Project Grant R21AI202743
Award Date 8/7/26
Completion Date 7/31/28
Dollars Obligated $198K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30303, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $197,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cross-protective immune mechanisms of combined mRNA and conventional influenza vaccines. The research develops new mRNA vaccine constructs encoding neuraminidase conjugated to a conserved M2E repeat, designed to enhance broad cross-protection against different...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $434,938 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanobodies as therapeutic agents against H5N1 influenza virus. The project develops potent, broadly neutralizing anti-H5N1 nanobodies with high stability and rapid production capability, engineered for efficient aerosol delivery to the lungs. The research targets the...
- The National Institute of Allergy and Infectious Diseases awarded University of Georgia Research Foundation, Inc. $805,866 on May 12, 2026, to develop and validate advanced predictive models for influenza vaccine responses under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will integrate longitudinally collected data with statistical and machine-learning methods to overcome limitations in current predictive models, which rely solely on static, pre-vaccination...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $661,313 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support development of a pan-influenza A vaccine. The research, led by Dr. Daniel Lingwood at the Ragon Institute of MGH, MIT and Harvard, focuses on elicitation of broadly neutralizing antibodies that protect against all influenza A viruses by triggering...
- The National Institute of Allergy and Infectious Diseases awarded $721,365 to the University of California Irvine on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a single-dose influenza vaccine platform that extends immune response breadth against viral variants. The funded research combines nanoparticles presenting H5 hemagglutinin antigen with thermo-responsive polymer depots that release antigen slowly, extending exposure time to elicit...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Washington University $765,798 on September 3, 2026, to develop a mucosal H5 influenza virus vaccine under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop a single-dose mucosal vaccine using a chimpanzee adenovirus vectored platform to confer robust protection against high-dose H5N1 challenge and transmission in pre-clinical...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $2,010,479 on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test outer membrane vesicle (OMV)-based vaccines against Neisseria gonorrhoeae using transgenic mouse models. The project generates OMV vaccines expressing binding-defective derivatives of conserved outer membrane transport proteins (TBPA/B, TDFH, and TDFJ)...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $695,041 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms underlying combination adjuvant-driven improvement of influenza vaccine responses. The research defines the innate immune signatures and adaptive immune responses elicited by existing and novel combination adjuvants as they relate to driving immune responses directed against influenza virus...
- The National Institute of Allergy and Infectious Diseases awarded Georgia TECH Research Corp $725,241 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop controlled-delivery HIV vaccine candidates using adjuvanted multivalent fusion peptide immunogens. The work focuses on five integrated components: safe, injectable hydrogels with tunable extended-release properties; virus-like particle platforms for multivalent antigen display;...